Fellow of The Academy of Medical Sciences, United Kingdom
Christopher E. Brightling mostly deals with Asthma, Immunology, Internal medicine, Sputum and COPD. His Asthma research incorporates elements of Eosinophilia, Respiratory disease and Exacerbation. He combines subjects such as Bronchoalveolar lavage, Lung, Eosinophilic and Airway with his study of Immunology.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Placebo and Surgery. His work on Sputum Cytology as part of general Sputum research is frequently linked to Absolute neutrophil count, thereby connecting diverse disciplines of science. His COPD study integrates concerns from other disciplines, such as Framingham Risk Score, Oncology, Cause of death, Chronic bronchitis and Prospective cohort study.
The scientist’s investigation covers issues in Asthma, Immunology, Internal medicine, COPD and Sputum. His Asthma research is multidisciplinary, relying on both Eosinophilia, Pathology, Intensive care medicine and Airway. His work deals with themes such as Disease and Eosinophilic, which intersect with Immunology.
His Internal medicine study combines topics in areas such as Gastroenterology, Placebo, Endocrinology and Cardiology. Christopher E. Brightling combines subjects such as Microbiome, Pulmonary disease, Exacerbation, Lung and Biomarker with his study of COPD. His Sputum research is multidisciplinary, incorporating perspectives in Exhaled nitric oxide, Respiratory disease, Haemophilus influenzae and Microbiology.
Asthma, Internal medicine, COPD, Immunology and Sputum are his primary areas of study. Christopher E. Brightling has included themes like Randomized controlled trial, Airway, Disease and Intensive care medicine in his Asthma study. His work deals with themes such as Gastroenterology and Placebo, which intersect with Internal medicine.
His work in COPD addresses issues such as Exacerbation, which are connected to fields such as Observational study and Biomarker. His Immunology study combines topics in areas such as Phenotype and Dysbiosis. His study on Sputum also encompasses disciplines like
His primary areas of study are Asthma, Internal medicine, COPD, Immunology and Sputum. His research in Asthma intersects with topics in Eosinophilia, Genome-wide association study and Intensive care medicine. Many of his research projects under Internal medicine are closely connected to In patient with In patient, tying the diverse disciplines of science together.
His work carried out in the field of COPD brings together such families of science as Benralizumab, Vital capacity, Pulmonary disease, Exacerbation and Dysbiosis. Christopher E. Brightling has researched Immunology in several fields, including Streptococcus pneumoniae, Phenotype, Receptor, Prostaglandin D2 and Airway. As a member of one scientific family, Christopher E. Brightling mostly works in the field of Sputum, focusing on Microbiome and, on occasion, Computational biology and Metagenomics.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs
J. Bousquet;H. J. Schünemann;B. Samolinski;P. Demoly.
The Journal of Allergy and Clinical Immunology (2012)
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Kian Fan Chung;Sally E. Wenzel;Jan L. Brozek;Andrew Bush.
European Respiratory Journal (2014)
Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report.
P Horby;W S Lim;Emberson.
The New England Journal of Medicine (2020)
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.
Ruth H Green;Christopher E Brightling;Susan McKenna;Beverley Hargadon.
The Lancet (2002)
Cluster analysis and clinical asthma phenotypes.
Pranab Haldar;Ian D. Pavord;Dominic E. Shaw;Michael A. Berry.
American Journal of Respiratory and Critical Care Medicine (2008)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar;Christopher E. Brightling;Beverley Hargadon;Sumit Gupta.
The New England Journal of Medicine (2009)
Mast-Cell Infiltration of Airway Smooth Muscle in Asthma
Christopher E. Brightling;Peter Bradding;Fiona A. Symon;Stephen T. Holgate.
The New England Journal of Medicine (2002)
Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids
R H Green;C E Brightling;G Woltmann;D Parker.
Evidence of a role of tumor necrosis factor alpha in refractory asthma.
Mike A. Berry;Beverley Hargadon;Maria Shelley;Debbie Parker.
The New England Journal of Medicine (2006)
Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Identification of Biologic Clusters and Their Biomarkers
Mona Bafadhel;Susan McKenna;Sarah Terry;Vijay Mistry.
American Journal of Respiratory and Critical Care Medicine (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: